Filing Flows › Immunocore Holdings (IMCR) › Guidance & outlook

Immunocore Holdings (IMCR) guidance and outlook

Immunocore Holdings' 10-Q filed Nov 6, 2026 makes 39 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 6, 2026

• We are progressing three late-stage clinical programs within our ImmTAC® portfolio, including KIMMTRAK and PRAME-targeted brenetafusp.
• We have incurred significant operating losses and expect to continue to incur significant expenses and operating losses for the near future.
• We do not expect to generate revenue from the sale of our other product candidates unless and until we successfully complete clinical development of and obtain regulatory approval for such product candidates.
• Until we can generate sufficient revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings, debt financings, government funding arrangements, collaborations and marketing and distribution and licensing arrangements.
• Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of future revenues, increased expenses or when or if we will be able to achieve or maintain profitability.
• We have achieved target enrollment of 540 patients in the registrational Phase 3 TEBE-AM trial, evaluating tebentafusp as monotherapy, and in combination with pembrolizumab, versus a control arm in patients with previously treated advanced cutaneous melanoma.
• We will present data from our Phase 1/2 trial evaluating brenetafusp alone and in combination with KIMMTRAK in HLA-A*02:01-positive patients with mUM, in a poster session, on Friday, November 6, at 12:00 p.m.
• We expect to present clinical data for brenetafusp from the ovarian and lung cohorts in the Phase 1/2 trial at a medical conference later this year.
• The amount of revenue recognized reflects the consideration to which we expect to be entitled, net of estimated deductions for rebates, chargebacks and product returns.
• These estimates consider contractual and statutory requirements, the expected payor and patient mix, sell-through data, our customers’ inventory levels, anticipated demand and the volume of customer purchase orders, internal data, and other information provided by our customers and third-party logistics providers, and in certain countries, pricing negotiations.
• We expect our R&D expenses to increase in the future as we advance existing and future product candidates into and through clinical studies and pursue further regulatory approval.
• At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any product candidates that we develop from our programs.

Immunocore Holdings' latest quarter

Questions

What does Immunocore Holdings expect?

We are progressing three late-stage clinical programs within our ImmTAC® portfolio, including KIMMTRAK and PRAME-targeted brenetafusp. We have incurred significant operating losses and expect to continue to incur significant expenses and operating losses for the near future. We do not expect to generate revenue from the sale of our other product candidates unless and until we successfully complete clinical development of and obtain regulatory approval for such product candidates.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.